Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intersect ENT, Inc.XENT · Entity 127294 | EVP & General Counsel | February 03, 2020 | February 05, 2020 |
| Pulmonx CorpLUNG · Entity 2359 | General Counsel | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intersect ENT, Inc.
Report date February 03, 2020 · Filed February 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,465 |
Reported balance
After 2020-02-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-03 · Grant · Acquired 10,740 · Balance 68,465 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units shall vest on the third anniversary from the date of grant provided that certain 30-day trailing average stock price (the "Average Closing Price") targets are achieved at any time during the three year period following the date of grant. 33 1/3%, 66 2/3% or 100% of the shares will vest if the Average Closing Price equals or exceeds specific stock price targets. F2: Includes 51,034 restricted stock units, of which 42,534 are performance based. |
| Common StockSEC Table I · non-derivative | Direct | 79,205 |
Reported balance
After 2020-02-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-03 · Grant · Acquired 10,740 · Balance 79,205 F3: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the grant date. F4: Includes 61,774 restricted stock units, of which 42,534 are performance based. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2030-02-03 | Direct | 21,270 |
Reported balance
After 2020-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-03 · Grant · Acquired 21,270 · Balance 21,270 F5: The vesting commencement date of the option is February 3, 2020. 1/8th of the shares subject to the option shall vest on August 3, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units shall vest on the third anniversary from the date of grant provided that certain 30-day trailing average stock price (the "Average Closing Price") targets are achieved at any time during the three year period following the date of grant. 33 1/3%, 66 2/3% or 100% of the shares will vest if the Average Closing Price equals or exceeds specific stock price targets.
F2: Includes 51,034 restricted stock units, of which 42,534 are performance based.
F3: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the grant date.
F4: Includes 61,774 restricted stock units, of which 42,534 are performance based.
F5: The vesting commencement date of the option is February 3, 2020. 1/8th of the shares subject to the option shall vest on August 3, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months.
Pulmonx Corp
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 361,827 |
Ending reported balance
After 2026-09-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-01 · Sale · Disposed 3,807 · Balance 372,354 F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. Row 2 · 2026-09-01 · Sale · Disposed 2,224 · Balance 370,130 F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024. Row 3 · 2026-09-01 · Sale · Disposed 3,476 · Balance 366,654 F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. Row 4 · 2026-09-01 · Sale · Disposed 4,827 · Balance 361,827 F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2017 Filed Jan 20, 2017 19:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000302 · primarydocument.xml · nonDerivative · entry 1 Lehman David Aaron · CIK 0001354228 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in equal annual installments over three years commencing on January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.